Integra Lifesciences Holdings (IART) Current Deferred Revenue (2009 - 2026)

Integra Lifesciences Holdings has reported Current Deferred Revenue for 18 years, with the latest figure at $21.7 million in Q2 2026.

• Quarterly Current Deferred Revenue fell 1.68% year-over-year to $21.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.7 million (down 1.68% YoY) and the FY2025 annual result came in at $23.0 million, up 16.99% from the prior year.
• Current Deferred Revenue fell to $21.7 million in Q2 2026 per IART's latest filing, from $22.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $23.0 million in Q4 2025 and troughed at $12.2 million in Q1 2022.
• A 5-year average of $18.0 million and a median of $17.4 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slipped 11.33% in 2024, then jumped 35.81% in 2025.
• Over 5 years, Current Deferred Revenue stood at $16.1 million in 2022, then increased by 0.78% to $16.3 million in 2023, then increased by 21.03% to $19.7 million in 2024, then grew by 16.99% to $23.0 million in 2025, then retreated by 5.76% to $21.7 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $21.7 million, $22.4 million, and $23.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.